The US Food and Drug Administration (USFDA) recorded a significant decline in serious regulatory findings at Indian drug manufacturing facilities between January and December 2025. Data reveals that 'official action indicated' (OAI) cases - the most severe classification - nearly halved over the past year.
Revenues from Bangladeshi patients have declined by 30% to 35% in 2024-2025. Bangladesh typically accounts for 70% to 75% of all medical visas issued by India.
Here's the lowdown from the Malayalam film industry.
'Thanks to Chhaava's success, I now have the creative freedom to pick and choose.'
Ram Charan and Janhvi Kapoor will come together in a film, tentatively titled RC 16.
'Fan armies are not just followers; they are a force of nature.'
'Every hospital now tracks length of stay closely.' 'More efficiency is brought into the system now.'
Amazon Prime Video has announced a huge number of assorted Web series and movies, and the slate sure looks interesting.
Kannada film Mythri (Friendship) released last Friday and has received positive reviews for its strong script, realistic plot, good performances and social message.
The Indian pharma industry is estimated to grow at 9-11 per cent in 2021-22 and in the next few quarters, it will be driven by domestic and emerging markets, according to ratings agency ICRA. In a sample of 21 Indian pharmaceutical companies, ICRA said revenue growth was moderate at 6.4 per cent in the second quarter of FY22, down from 16 per cent in the first quarter of 2021-22. The normalisation of the base and pricing pressures in the US market were the major reasons for slowing growth momentum in Q2 FY22, even as growth under domestic and emerging markets remained healthy, ICRA said in a statement.
Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of inflation and pricing pressures in the global markets. While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023. The industry believes that in view of India's G20 Presidency, digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023.
The actor playing a business tycoon in his upcoming film.
Karnataka Chief Minister Siddaramaiah has announced an inquiry into alleged irregularities in selection of candidates by the state public Service Commission for gazetted probationer posts.
A group of women traveled 5000 kilometers in India over eight cities in 28 days to spread the message of women's empowerment and safety while on the road.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances